NCT02414516View on ClinicalTrials.gov

A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

August 31, 2019

Conditions
Solid Tumor
Interventions
DRUG

OBP-801

OBP-801 will be administered IV

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

Sponsors
All Listed Sponsors
lead

Oncolys BioPharma Inc

INDUSTRY